Crenezumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Crenezumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target 1-40-β-amyloid
Clinical data
Legal status
?
Identifiers
CAS number 1174395-19-7 N
ATC code None
Chemical data
Formula C6442H9966N1706O2018S40 
Mol. mass 144.88 kDa
 N (what is this?)  (verify)

Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease.[1] Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc.[2] Its original name RG7412 refers to its inventor[3] at AC Immune.

In May 2012, it was announced that the efficacy of crenezumab will be tested in a five-year trial against early-onset Alzheimer's disease.[4] The $100 million trial will be funded by Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health. Participants in the study will be recruited from an extended family in and around Medellín, Colombia.[5] Approximately one-third of the 5,000 family members carry an autosomal dominant allele of presenilin-1 (PSEN1) that causes the early-onset form of Alzheimer's disease. The trial will test the effect of the drug on 300 individuals who have the PSEN1 mutation, but do not yet show symptoms of the disease.[4]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab". American Medical Association. 
  2. ^ "Roche Signs First Alzheimer's Deal Of 2011 As Crucial Progress Awaited"
  3. ^ http://www.faqs.org/patents/app/20100098707
  4. ^ a b "Testing a Drug That May Stop Alzheimer’s Before It Starts"
  5. ^ "Alzheimer’s Stalks a Colombian Family"